UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 258

Sortiert nach

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205

2017

Volltextzugriff (PDF)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

British journal of cancer, 2020-03, Vol.122 (5), p.603-612

2020

Volltextzugriff (PDF)

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer

European journal of clinical investigation, 2021-07, Vol.51 (7), p.e13535-n/a

2021

Volltextzugriff (PDF)

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Cancer treatment reviews, 2013-12, Vol.39 (8), p.935-946

2013

Volltextzugriff (PDF)

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Journal of clinical oncology, 2008-02, Vol.26 (5), p.729-735

2008

Volltextzugriff (PDF)

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

The lancet oncology, 2013-03, Vol.14 (3), p.244-248

2013

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2159-2165

2014

Volltextzugriff (PDF)

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

Journal of clinical oncology, 2013-07, Vol.31 (21), p.2692-2698

2013

Volltextzugriff (PDF)

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1987-1992

2008

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3859-3865

2007

Volltextzugriff (PDF)

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

Journal of clinical oncology, 2010-07, Vol.28 (21), p.3422-3428

2010

Volltextzugriff (PDF)

The 41st David A. Karnofsky Memorial Award Lecture: Academic Research Worldwide—Quo Vadis?

Journal of clinical oncology, 2014-02, Vol.32 (4), p.347-354

PICCART-GEBHART, Martine J

2014

Volltextzugriff (PDF)

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

Nature reviews. Clinical oncology, 2010-01, Vol.7 (1), p.22-36

2010

Volltextzugriff (PDF)

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1980-1986

2008

Volltextzugriff (PDF)

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

JNCI : Journal of the National Cancer Institute, 2017-01, Vol.109 (1), p.djw192

2017

Volltextzugriff (PDF)

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Journal of clinical oncology, 2017-03, Vol.35 (8), p.878-884

2017

Volltextzugriff (PDF)

New Developments in Hormone Receptor–Positive Disease

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (S1), p.40-50

Piccart‐Gebhart, Martine J.

2011

Volltextzugriff (PDF)

New generation of breast cancer clinical trials implementing molecular profiling

Cancer biology & medicine, 2016-06, Vol.13 (2), p.226-235

2016

Volltextzugriff (PDF)

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042

2016

Volltextzugriff (PDF)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

NPJ breast cancer, 2021-09, Vol.7 (1), p.125-125, Article 125

2021

Volltextzugriff (PDF)

New Developments in Hormone Receptor–Positive Disease

The oncologist (Dayton, Ohio), 2010-11, Vol.15 (S5), p.18-28

Piccart‐Gebhart, Martine J.

2010

Volltextzugriff (PDF)

1 – 25 von 258

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(248)

Publikationsform

Artikel
(254)
Buchkapitel
(1)
Bücher
(1)
Berichte
(1)
Texte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(134)
Life Sciences & Biomedicine
(133)
Oncology
(120)
Humans
(117)
Female
(114)
Breast Neoplasms - Drug Therapy
(89)
Breast Cancer
(80)
Breast Neoplasms - Pathology
(56)
Trastuzumab
(54)
Middle Aged
(51)
Tumors
(49)
Adult
(44)
Chemotherapy, Adjuvant
(43)
Aged
(39)
Treatment Outcome
(37)
Antineoplastic Agents - Therapeutic Use
(34)
Biological And Medical Sciences
(34)
Breast Neoplasms - Genetics
(34)
Medical Sciences
(34)
Chemotherapy
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

Clinical Application of the 70-Gene Profile: The MINDACT Trial

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

The 41st David A. Karnofsky Memorial Award Lecture: Academic Research Worldwide—Quo Vadis?

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

New Developments in Hormone Receptor–Positive Disease

New generation of breast cancer clinical trials implementing molecular profiling

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

New Developments in Hormone Receptor–Positive Disease

Suchergebnisse filtern